Skip to main content
. Author manuscript; available in PMC: 2016 Aug 23.
Published in final edited form as: Leukemia. 2015 Jul 23;30(1):190–199. doi: 10.1038/leu.2015.194

Figure 3.

Figure 3

Selinexor (KPT-330) induces only a moderate reduction of the leukemia burden in NSG mice engrafted with primary AML-CK2 cells. (a) Percentage engraftment of human AML-CK2 cells in the bone marrow of NSG mice before and after treatment with vehicle or selinexor. (b) Human CD45+ cells counts per femur and tibia in NSG mice transplanted with AML-CK2 cells before and after treatment with vehicle or selinexor. (c) Spleen weights of mice transplanted with human AML-CK2 cells before and after treatment with vehicle or selinexor. (d–f) Hematoxilin and eosin staining of the femur and spine bones and spleen of mice transplanted with AML-CK2 cells isolated from animals before treatment (d) and after treatment with either vehicle (e) or selinexor (f). Each symbol denotes an individual animal (n =4–8 per group). Scale bar (white) =10 µm. White arrows point to the AML blast cells. Error bars represent mean ±s.e.m. values; *P < 0.05 by unpaired t-test for comparisons between the indicated groups. **P < 0.001.